Subcutaneous Implantable Defibrillator Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type(Single Zone, Dual Zone, Others), By End User(Hospital, Clinics, Ambulatory surgical Centres, Cardiac catheterization laboratory, and Others) By Region(North America, Europe, Asia Pacific, Latin America, Middle East & Africa)

Subcutaneous Implantable Defibrillator Market size was valued at US$ 8,454.8 million in 2023, growing at a CAGR of 4.8%  from 2024 - 2030 over the forecast year. A subcutaneous implantable cardioverter defibrillator is a type of implantable cardioverter defibrillator. An ICD is an electronic medical device that helps prevent sudden cardiac death. The subcutaneous version of the device goes under your skin. Healthcare providers recommend ICDs for people with certain cardiac conditions to monitor heart rhythm. When the device detects a very fast, abnormal heart rhythm, it delivers a shock to your chest to reset your heart rhythm. This is defibrillation. The global market of subcutaneous implantable defibrillators is expected to be driver by key advantages of subcutaneous implantable defibrillators over conventional implantable defibrillators, such as the placement of electrodes near the heart rather than on the heart in the case of conventional fibrillatory which reduces risk and longer shelf life, and ease of insertion and removal of a subcutaneous defibrillator. Also, increasing incidence of cardiovascular disease, increasing geriatric population around the world, changes in lifestyle, sedentary lifestyle, changing diets, increasing stress, increased consumption of alcohol, increased smoking, rising prevalence of strokes, and increasing technological advancement in the medical devices industry are some of the factors responsible for the growth of the Subcutaneous Implantation defibrillators market during the forecast period. However issues related to the use of automated implantable and automated defibrillators, frequent product recalls, and a lack of awareness about sudden cardiac arrest in developing nations are expected to hinder the growth of the Subcutaneous Implantable Defibrillators market during the forecast period. Other factors such as limited reimbursement in developed nations, and lack of infrastructures, particularly in underdeveloped and developed countries are also expected to hinder the growth of the Subcutaneous Implantable Defibrillator market

 Subcutaneous Implantable Defibrillator Market Key Developments:

• In July 2020, Abbott received FDA approval for its next-generation ICD and CRT-Ds under the brand name Gallant.
• In July 2020, Koninklijke Philips received FDA pre-market approval for Healthstart FR3 and Healthstart FRX AED.